Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | DPP4 | P27487 | 8/20 | 0.43 |
| ▸ | FAP | Q12884 | 4/20 | 0.43 |
| ▸ | PREP | P48147 | 2/20 | 0.43 |
| ▸ | ACE | P12821 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.41 |
| ▸ | MMP1 | P03956 | 1/20 | 0.40 |
| ▸ | MMP9 | P14780 | 1/20 | 0.40 |
| ▸ | MMP13 | P45452 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2744394 | 1.00 | MEN1 (0.48) | MEN1ALDH1A1TSHRKMT2ADPP4 | |
| SCHEMBL13580680 | 0.90 | MEN1 (0.43) | MEN1ALDH1A1TSHRKMT2ADPP4 | |
| SCHEMBL1000948 | 0.88 | ACE (0.53) | MEN1ALDH1A1TSHRKMT2AFAP | |
| SCHEMBL8352289 | 0.88 | MEN1 (0.49) | MEN1ALDH1A1TSHRKMT2ADPP4 | |
| SCHEMBL14979025 | 0.88 | MEN1 (0.49) | MEN1ALDH1A1TSHRKMT2ADPP4 | |
| SCHEMBL1925210 | 0.88 | ACE (0.53) | MEN1ALDH1A1TSHRKMT2AFAP | |
| SCHEMBL8131025 | 0.88 | DPP4 (0.43) | MEN1ALDH1A1TSHRKMT2ADPP4 | |
| SCHEMBL10881232 | 0.87 | DPP4 (0.49) | DPP4ACESMN1; SMN2KLK5 | |
| SCHEMBL6468703 | 0.87 | KLK5 (0.53) | MEN1ALDH1A1TSHRKMT2ADPP4 | |
| SCHEMBL14235217 | 0.87 | KLK5 (0.53) | MEN1ALDH1A1TSHRKMT2ADPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025237891-A1 | QUINOLINE-2-CARBOXAMIDE DERIVATIVES AS RAD51 INHIBITORS FOR THE TREATMENT OF CANCER | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2025-11-20 | — | — | WO | disclosed |
| US-20250235566-A1 | TRISLINKER-CONJUGATED DIMERIC LABELING PRECURSORS AND RADIOTRACERS DERIVED THEREFROM | Medianezia GmbH (DE) | 2025-07-24 | — | — | US | disclosed |
| EP-4351663-A1 | TRISLINKER-CONJUGATED DIMERIC LABELLING PRECURSORS AND RADIOTRACERS DERIVED THEREFROM | Medianezia GmbH (DE) | 2024-04-17 | — | — | EP | disclosed |
| US-11858924-B2 | N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-quinoline-4-carboxamides | ASTRAZENECA (SE) | 2024-01-02 | — | — | US | disclosed |
| US-20230312550-A1 | N-(2-(4-CYANOTHIAZOLIDIN-3-YL)-2-OXOETHYL)-QUINOLINE-4-CARBOXAMIDES | ASTRAZENECA AB (SE) | 2023-10-05 | — | — | US | disclosed |
| WO-2022258637-A1 | TRISLINKER-CONJUGATED DIMERIC LABELLING PRECURSORS AND RADIOTRACERS DERIVED THEREFROM | Atoms for Cure GmbH (DE) | 2022-12-15 | — | — | WO | disclosed |
| US-20210369877-A1 | MARKING PRECURSOR WITH SQUARIC ACID COUPLING | SCV- Spezial Chemikalien Vertrieb GmbH (DE) | 2021-12-02 | — | — | US | disclosed |
| EP-2804859-B1 | NOVEL FAP INHIBITORS | UNIV ANTWERPEN (BE) | 2019-06-12 | — | — | EP | disclosed |
| EP-2246347-B1 | DICYCLOAZAALKANE DERIVATES, PREPARATION PROCESSES AND MEDICAL USES THEREOF | SHANGHAI HENGRUI PHARM CO LTD (CN) | 2016-09-28 | — | — | EP | disclosed |
| US-9346814-B2 | FAP inhibitors | Universiteit Antwerp (BE) | 2016-05-24 | — | — | US | disclosed |
| US-20100311747-A1 | DICYCLOAZAALKANE DERIVATES, PREPARATION PROCESSES AND MEDICAL USES THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO. LTD. (CN) | 2010-12-09 | — | — | US | disclosed |
| US-20100311747-A1 | DICYCLOAZAALKANE DERIVATES, PREPARATION PROCESSES AND MEDICAL USES THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO. LTD. (CN) | 2010-12-09 | — | — | US | disclosed |
| WO-2009142842-A9 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2010-11-25 | — | — | WO | disclosed |
| WO-2009142842-A2 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2009-11-26 | — | — | WO | disclosed |
| US-20090176847-A1 | Dicyclooctane Derivatives, Preparation Processes and Medical Uses Thereof | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2009-07-09 | — | — | US | disclosed |
| US-20090176847-A1 | Dicyclooctane Derivatives, Preparation Processes and Medical Uses Thereof | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2009-07-09 | — | — | US | disclosed |
| WO-2009005677-A2 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2009-01-08 | — | — | WO | disclosed |
| EP-2006284-A1 | DICYCLOOCTANE DERIVATES, PREPARATION PROCESSES AND MEDICAL USES THEREOF | Shanghai Hengrui Pharmaceutical Co. Ltd. (CN) | 2008-12-24 | — | — | EP | disclosed |
| WO-2008137779-A2 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2008-11-13 | — | — | WO | disclosed |
| WO-2007015824-A2 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2007-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176847-A1 | Dicyclooctane Derivatives, Preparation Processes and Medical Uses Thereof | DPP4, DPP7, DPP8 | MEN1 1501/4885ALDH1A1 1142/4885TSHR 4125/4885 |
| US-20100311747-A1 | DICYCLOAZAALKANE DERIVATES, PREPARATION PROCESSES AND MEDICAL USES THEREOF | DPP4, DPP8, DPP7 | MEN1 2775/4885ALDH1A1 451/4885TSHR 3534/4885 |
| US-20250235566-A1 | TRISLINKER-CONJUGATED DIMERIC LABELING PRECURSORS AND RADIOTRACERS DERIVED THEREFROM | TK1, TK2, TMT1A | MEN1 385/4885ALDH1A1 2879/4885TSHR 81/4885 |
| US-20230312550-A1 | N-(2-(4-CYANOTHIAZOLIDIN-3-YL)-2-OXOETHYL)-QUINOLINE-4-CARBOXAMIDES | FAP, PREP, CTRL | MEN1 1482/4885ALDH1A1 1593/4885TSHR 1989/4885 |
| US-20210369877-A1 | MARKING PRECURSOR WITH SQUARIC ACID COUPLING | SCLY, SRRT, CS | MEN1 2064/4885ALDH1A1 1074/4885TSHR 162/4885 |
| US-11858924-B2 | N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-quinoline-4-carboxamides | FAP, PREP, CTRL | MEN1 1482/4885ALDH1A1 1593/4885TSHR 1989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.